Biotech Values

[DewDiligence]

As a biotech investor, are you concerned that pretty much every presidential candidate seems to have a plan to cut drug costs?

Yes, to some degree. However, major changes in the US prescription-drug business won’t happen without support from both houses of Congress and the President. Hence, any plan that actually gets enacted in the next few years is apt to be considerably more modest than the worst-case scenarios.